CASE REPORT

SARS-CoV-2 late shedding may be infectious between immunocompromised hosts

Ville Kaila, Simo Sirkeo, Soile Blomqvist, Juha Rannikko, Hanna Viskari, Tiina Lyly-Yrjänäinen and Jaana Syrjänen

Department of Infectious Disease, Tampere University Hospital, Tampere, Finland; Expert Microbiology, National Institute for Health and Welfare, Helsinki, Finland; Department of Oncology, Tampere University Hospital, Tampere, Finland

ABSTRACT

Background: Immunocompromised patients shed SARS-CoV-2 for extended periods, but to our knowledge person-to-person transmission from late shedding has not been reported.

The case: We present a case in which a COVID-19 patient infected another over 28 days after the patient’s initial symptoms, past current guideline recommendations of 20 days for length of isolation in immunocompromised patients. Whole genome sequencing of their viruses was performed to ascertain the transmission.

Discussion: Severely immunocompromised patients, whose clearance of the virus is impaired, may remain infectious for extended periods. Caution should be taken particularly in hospital settings where lapses in isolation procedures might pose increased risk, especially to other immunocompromised patients.

KEYWORDS
Covid
SARS-CoV-2
immunosuppression
transmission
late shedding

ARTICLE HISTORY

Received 30 April 2021
Revised 26 May 2021
Accepted 2 June 2021

CONTACT
Ville Kaila
ville.kaila@pshp.fi
Department of Infectious Disease, Tampere University Hospital, Finn-Medi 2 building, 6th floor, Biokatu 6, 33521 Tampere, Finland

© 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
The world has been in the grip of a pandemic caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its associated disease (COVID-19) for over a year now. Several reports have been published showing that some patients shed the virus for prolonged periods [1–3]. Patients receiving chemotherapy are generally severely immunosuppressed and, as such, susceptible to a wide variety of infections also with poorer outcomes. It is, therefore, not surprising that the same applies for cancer patients faced off with COVID-19 [4]. When compared to immunocompetent patients, immunocompromised patients also shed the virus for longer periods of time [1,3,5]. Nonetheless, to our knowledge no studies to date have reported cases of person-to-person transmission in this late shedding and, hence, the clinical and epidemiological significance has therefore remained unclear. However, there is evidence from other viral infections such as influenza and noroviral diarrhoea showing that severely immunocompromised patients may shed the virus and remain infectious for extended periods of time due to impaired clearance [6,7]. Current CDC [8] and ECDC [9] guidelines recommend the duration of isolation for severely immunocompromised COVID-19 patients to be up to 20 days. We present a case that infers prolonged infectiousness, even past 20 days, to be possible with immunosuppressed patients and poses it to be a matter of consequence especially in hospital settings.

**Description**

Patient A, a 73-year-old woman with diffuse large B-cell lymphoma and Waldenström macroglobulinemia, was exposed to COVID-19 on the 11th of December 2020. The patient had received her third course of rituximab, cyclophosphamide, doxorubicin and prednisone on the 1st of December and was chronically cytopenic due to the treatment and the bone marrow-affecting malignancy itself. The patient developed fatigue on the 15th of December and on the 21st of December she was admitted to Tampere University Hospital (TaUH) oncology ward with fever and tested positive for COVID-19 (cycle thresholds [Ct] 28.71 for ORF1a/b target and 29.37 for envelope gene [E] target). The patient initially improved, and was discharged to home isolation.

On the 12th of January, 28 days after the onset of symptoms the patient was admitted to TaUH oncology ward to continue lymphoma treatment. The patient still reported fatigue and malaise. The 13th of January the patient became febrile and ceftriaxone was initiated. The patient shared a room with Patient B, a 77-year-old woman scheduled to receive radiotherapy together with rituximab and temozolomide for primary central nervous system lymphoma, for a total of 7 days.

On the 20th of January, Patient B was transferred to a secondary treatment facility where the patient had also resided prior to her visit to the oncology ward. On the 24th of January Patient B became febrile and tested positive for COVID-19 (Ct 13.20 for ORF1a/b and 13.31 for E). Patient A was still COVID-positive on the 30th of January (Ct 24.8 for E and 23.9 for RdRp) and was also found to be seronegative for IgG-antibodies against SARS-CoV-2 on the 25th of January, which may indicate an insufficient immune response. Eventually both patients succumbed to COVID-related respiratory failure.

Whole genome sequencing of the SARS-CoV-2 samples from these patients was performed using the ARTIC protocol [10] (Table 1), followed by phylogenetic analysis with Nextstrain [11] by the Expert Microbiology Unit of the National Institute for Health and Welfare. Both viruses were of the genetic lineage B.1.1.241 and nearly identical. Patient A’s second sample, taken over a month after the first, was also nearly identical to the first and to patient B’s sample. The sequences will be submitted to Gisaid database. These analyses support our postulate that Patient A, over 28 days after her initial symptoms, had an insufficient immune response. Eventually both patients succumbed to COVID-related respiratory failure.

Table 1. Sequence comparison: The variations on the left were observed in both samples when compared to the Wuhan reference strain.

| Nucleotide variations in both samples vs Wuhan reference | Individual variations between samples |
|----------------------------------------------------------|---------------------------------------|
| C241T C2695T G18538T G22616T C28472T G28881A G28882A | Patient Date of sample Nt variations Aa variations |
| C2307T C8092T A11782G G24586T G28883C C28253T | Dec 21st 0 0 |
| G15526T C28472T G28881A G28882A | Jan 24th C5178T ORF1a:T16381 |
| C3037T C8092T A11782G G24586T G28883C | C11454T ORF1a:A3730V |
| C2695T C3037T C8092T A11782G G24586T | S1:V3G S2:V5F S3:A352S S:G614A |
| C2695T C3037T C8092T A11782G G24586T | S1:V3G S2:V5F S3:A352S S:G614A |
| G22616T A23403G G24586T | N:P67S N:R203K N:G204R ORF1b:P314L |
| G22616T A23403G G24586T | ORF1b:K1383R ORF1b:V1691L |
| G22616T A23403G G24586T | A Jan 30th C5178A ORF1a:T16381 |
| G22616T A23403G G24586T | S:S50L N:P67S N:R203K N:G204R ORF1b:P314L |
| G22616T A23403G G24586T | ORF1b:K1383R ORF1b:V1691L |
| G22616T A23403G G24586T | A Jan 30th C5178A ORF1a:T16381 |
| G22616T A23403G G24586T | S:S50L N:P67S N:R203K N:G204R ORF1b:P314L |
| G22616T A23403G G24586T | ORF1b:K1383R ORF1b:V1691L |
| G22616T A23403G G24586T | A Jan 30th C5178A ORF1a:T16381 |
| G22616T A23403G G24586T | S:S50L N:P67S N:R203K N:G204R ORF1b:P314L |
| G22616T A23403G G24586T | ORF1b:K1383R ORF1b:V1691L |
| G22616T A23403G G24586T | A Jan 30th C5178A ORF1a:T16381 |
| G22616T A23403G G24586T | S:S50L N:P67S N:R203K N:G204R ORF1b:P314L |
| G22616T A23403G G24586T | ORF1b:K1383R ORF1b:V1691L |
| G22616T A23403G G24586T | A Jan 30th C5178A ORF1a:T16381 |
infected patient B. Furthermore, contact tracing did not reveal any other possible sources for Patient B’s infection since the Patient B’s hospitalisation on the 21st of Dec. Patient A’s reinfection was considered as a possibility, but is unlikely, since Patient B’s strain was almost identical to Patient A’s both samples and the two had not previously met.

Discussion

The implication is that severely immunocompromised patients, whose clearance of the virus is impaired, may remain infectious for extended periods. Caution should be taken particularly in hospital settings where lapses in isolation procedures might pose increased risk, especially to other immunocompromised patients. In the COVID-19 case described here, the 20 days of isolation was not sufficient. Furthermore, prolonged shedding may increase potential accumulation of point mutations up to emergence of new SARS-CoV-2 variants. Further studies are needed to ascertain this implication and to determine a sufficient duration of isolation for severely immunosuppressed patients. A reverse transcriptase polymerase chain reaction (RT-PCR) test may remain positive for a long time with poor correlation to infectivity or shedding of viable virus [2] and could lead to unnecessarily long isolation periods and delays in chemotherapy. SARS-CoV-2 antibodies may be of additional value in assessing a patient’s ability to contain shedding and, thus, help determine the length of the isolation. Additionally, a new onset of fever on an immunocompromised individual, whose isolation has ended fairly recently, should prompt a reassessment of the duration of isolation procedures.

Acknowledgements

We wish to thank the rest of the Expert Microbiology Unit of the National Institute for Health and Welfare for the whole genome sequencing.

Disclosure statement

None to declare.

References

[1] Cogliati Dezza F, Oliva A, Cancelli F, et al. Determinants of prolonged viral RNA shedding in hospitalized patients with SARS-CoV-2 infection. Diagn Microbiol Infect Dis. 2021; 100(2):115347.
[2] Zapor M. Persistent detection and infectious potential of SARS-CoV-2 virus in clinical specimens from COVID-19 patients. Viruses. 2020;12(12):1384.
[3] Hensley MK, Bain WG, Jacobs J, et al. Intractable Coronavirus Disease 2019 (COVID-19) and prolonged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication in a chimeric antigen receptor-modified T-cell therapy recipient: a case study. Clin Infect Dis. 2021: ciab072.
[4] Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21(3):335–337.
[5] Aydillo T, Gonzalez-Reiche AS, Aslam SA, et al. Shedding of viable SARS-CoV-2 after immunosuppressive therapy for cancer. N Engl J Med. 2020;383(26):2586–2588.
[6] Roosenhoff R, van der Vries E, van der Linden A, et al. Influenza A/H3N2 virus infection in immunocompromised ferrets and emergence of antiviral resistance. PLoS One. 2018;13(7):e0200849.
[7] Davis A, Cortez V, Grodzki M, et al. Infectious norovirus is chronically shed by immunocompromised pediatric hosts. Viruses. 2020;12(6):619.
[8] Centers for Disease Control and Prevention guidance for Discontinuation of Transmission-Based Precautions and Disposition of Patients with SARS-CoV-2 Infection in Healthcare Settings [updated 2021 Jun 2]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/hcp/disposition-hospitalized-patients.html.
[9] European Centre for Disease Prevention and Control guidance for discharge and ending of isolation of people with COVID-19 [updated 2020 Oct 16]. Available from: https://www.ecdc.europa.eu/sites/default/files/documents/Guidance-for-discharge-and-ending-of-isolation-of-people-with-COVID-19.pdf.
[10] Artic Network protocols for sequencing SARS-CoV-2. Available from: https://artic.network/ncov-2019.
[11] Nextstrain database for pathogen genome data. Available from: https://nextstrain.org.